Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States

Arthritis Care and Research

Volumn 65, Issue 10, 2013, Pages 1564-1572

  Hone, Devon ^a,b   Cheng, Annie ^c   Watson, Crystal ^d   Huang, Baisong ^a   Bitman, Bojena ^e   Huang, Xing Yue ^e   Gandra, Shravanthi R ^f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b McKesson Canada   (Canada)

^c McKesson Specialty Care Solutions   (United States)

^d BIOGEN   (United States)

^e Searle   (United States)

^f AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE;

ABSENTEEISM; ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG COST; FEMALE; HUMAN; INCOME; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; TELEPHONE INTERVIEW; UNITED STATES; WORK DISABILITY; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE;

ABSENTEEISM; ACTIVITIES OF DAILY LIVING; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; EFFICIENCY; EMPLOYMENT; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SICK LEAVE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WORK CAPACITY EVALUATION; WORKLOAD;

EID: 84884994555     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22022     Document Type: Article

References (37)

1. Burton W, Morrison A, Maclean R, Ruderman E,. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006; 56: 18-27.
2. Filipovic I, Walker D, Forster F, Curry AS,. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1083-90.
3. Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004; 51: 488-97.
4. Eberhardt K, Larsson BM, Nived K, Lindqvist E,. Work disability in rheumatoid arthritis: development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007; 34: 481-7.
5. Sullivan PW, Ghushchyan V, Huang XY, Globe DR,. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol 2010; 37: 544-9.
6. Wolfe F, Allaire S, Michaud K,. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007; 34: 2211-7.
7. Zhang W, Anis AH,. The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol 2011; 30 Suppl 1: S25-32.
8. Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford) 2009; 48: 1283-9.
9. Barrett EM, Scott DG, Wiles NJ, Symmons DP,. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford) 2000; 39: 1403-9.
10. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M,. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010; 26: 77-90.
11. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L,. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 3046-54.
12. Globe D, Mazonson P, Santas C, Murphy R, Cheng A, Huang X, et al. Impact of etanercept treatment on absenteeism and productivity: the Work Loss and Productivity Survey. Am Health Drug Benefits 2010; 3: 191-200.
13. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008; 59: 1467-74.
14. Van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH,. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken) 2010; 62: 226-34.
15. Allaart CF, Breedveld FC, Dijkmans BA,. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol Suppl 2007; 80: 25-33.
16. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P,. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 2010; 49: 1900-10.
17. Reilly MC, Zbrozek AS, Dukes EM,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
18. WPAI general information. URL: http://www.reillyassociates.net/.
19. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH,. Validity of the Work Productivity and Activity Impairment Questionnaire: general health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12: R177.
20. 2000 Current Population Survey, March Supplement. URL: http://www.bls.gov/cps/.
21. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59: 234-40.
22. Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67: 1229-34.
23. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, on behalf of the Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560-8.
24. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009; 1173: 837-46.
25. Zhang W, Gignac MA, Beaton D, Tang K, Anis AH,. Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J Rheumatol 2010; 37: 1805-14.
26. DiBonaventura MD, Cappelleri JC, Joshi AV,. Association between pain severity and health care resource use, health status, productivity and related costs in painful diabetic peripheral neuropathy patients. Pain Med 2011; 12: 799-807.
27. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE,. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 314-20.
28. Lofland JH, Pizzi L, Frick KD,. A review of health-related workplace productivity loss instruments. Pharmacoeconomics 2004; 22: 165-84.
29. May 2009 national occupational employment and wage estimates. URL: http://www.bls.gov/oes/2009/may/oes-nat.htm.
30. Analysource. First Databank. URL: www.firstdatabank.com.
31. Zhang W, Bansback N, Kopec J, Anis AH,. Measuring time input loss among patients with rheumatoid arthritis: validity and reliability of the Valuation of Lost Productivity questionnaire. J Occup Environ Med 2011; 53: 530-6.
32. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
33. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
34. Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF,. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 2010; 69: 126-31.
35. Zhang W, Bansback N, Beaton D, Lacaille D, Gignac M, Badley E, et al. How is reduced performance at work (presenteeism) associated with measures of disease severity in patients with osteoarthritis (OA) and rheumatoid arthritis (RA)? [abstract]. Ann Rheum Dis 2008; 67 Suppl 2: 583.
36. Tang K, Beaton DE, Boonen A, Gignac MA, Bombardier C,. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care Res (Hoboken) 2011; 63 Suppl: S337-49.
37. Kobelt G, Eberhardt K, Geborek P,. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63: 4-10.